Literature DB >> 1800380

Comparative in vitro activity of cefpodoxime against anaerobes other than Bacteroides fragilis.

H Werner1, W R Heizmann, M Höflsauer.   

Abstract

To assess the in vitro activity of cefpodoxime against anaerobic respiratory tract and oropharyngeal pathogens 77 strains belonging to 18 gram-negative and 7 gram-positive species were studied by means of agar dilution tests. For comparison cefuroxime, amoxicillin, amoxicillin + clavulanic acid and clindamycin were also tested. Cefpodoxime was found to be active at concentrations of less than or equal to 0.125 mg/l against Prevotella oralis, Prevotella buccalis, Prevotella bivia, Porphyromonas asaccharolytica, Bacteroides corporis, Bacteroides gracilis, Fusobacterium necrophorum, Fusobacterium naviforme and Propionibacterium acnes. Prevotella oris, Prevotella buccae, Fusobacterium nucleatum, Peptostreptococcus asaccharolyticus, and Ruminococcus bromii were inhibited at concentrations of less than or equal to 1 mg/l and Prevotella denticola, Prevotella melaninogenica, Prevotella intermedia, Porphyromonas gingivalis, Bacteroides pneumosintes, and Peptostreptococcus micros at concentrations of less than or equal to 4 mg/l. Strains of Veillonella parvula were inhibited by cefpodoxime at 0.25-8 mg/l, and single strains of Peptostreptococcus anaerobius and Peptostreptococcus magnus showed MICs of 32 and 64 mg/l, respectively. The results obtained warrant the use of cefpodoxime in therapy of anaerobic and mixed aerobic-anaerobic infections of the upper and lower respiratory tract and similar infections not involving Bacteroides fragilis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1800380     DOI: 10.1007/BF01645372

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  7 in total

1.  In vitro activity of U-76,252 (CS-807), a new oral cephalosporin.

Authors:  R J Fass; V L Helsel
Journal:  Antimicrob Agents Chemother       Date:  1988-07       Impact factor: 5.191

2.  In vitro and in vivo antibacterial activities of CS-807, a new oral cephalosporin.

Authors:  Y Utsui; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

3.  Bacteroides gracilis, an important anaerobic bacterial pathogen.

Authors:  C C Johnson; J F Reinhardt; M A Edelstein; M E Mulligan; W L George; S M Finegold
Journal:  J Clin Microbiol       Date:  1985-11       Impact factor: 5.948

4.  Characterization of Wolinella spp., Campylobacter concisus, Bacteroides gracilis, and Eikenella corrodens by polyacrylamide gel electrophoresis.

Authors:  A C Tanner
Journal:  J Clin Microbiol       Date:  1986-10       Impact factor: 5.948

5.  Antimicrobial activity and disk diffusion susceptibility testing of U-76,253A (R-3746), the active metabolite of the new cephalosporin ester, U-76,252 (CS-807).

Authors:  R N Jones; A L Barry
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

6.  Antibacterial activities of cefpodoxime, cefixime, and ceftriaxone.

Authors:  C C Knapp; J Sierra-Madero; J A Washington
Journal:  Antimicrob Agents Chemother       Date:  1988-12       Impact factor: 5.191

7.  In vitro activity of flomoxef compared to moxalactam, cefoxitin, cefotaxime, and clindamycin against anaerobes.

Authors:  H Werner; W Heizmann; G Luft
Journal:  Arzneimittelforschung       Date:  1988-11
  7 in total
  2 in total

Review 1.  Fusobacterium necrophorum infections: virulence factors, pathogenic mechanism and control measures.

Authors:  Z L Tan; T G Nagaraja; M M Chengappa
Journal:  Vet Res Commun       Date:  1996       Impact factor: 2.459

Review 2.  Cefpodoxime proxetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.

Authors:  J E Frampton; R N Brogden; H D Langtry; M M Buckley
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.